Superworth

Silo Pharma price to sales ratio SILO

Market value divided by revenue over the last twelve months, since 2021.

Today, Nov 2, 2026
35.5×
5-year median
76.3×
Against its 5-year history
3rd
percentile: 0 is its lowest day, 100 its highest
5-year range
26.7× to 198×
Peer median
0.4×

Silo Pharma's price to sales ratio is 35.5× as of Nov 2, 2026.

That is below its 5-year median of 76.3×, lower than on 97% of days in the last 5 years.

Over that time it ranged from 26.7× in May 2025 to 198× in Aug 2021.

The median for 7 healthcare stocks of a similar size is 0.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far35.5×34.7×101×
202567.4×26.7×123×
202458.5×37.4×95.6×
2023n/m a value too high to mean anything
202297.6×90.0×124×
202191.7×86.5×198×

Against its peers

Companies in Healthcare nearest Silo Pharma's size, closest first, today.

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Silo Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.